Category Archives: Oncology

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer (FLAURA)

November 20, 2017- Interviewed by Steven E. Greer, MD We interviewed Emory University oncologist Suresh S. Ramalingam, M.D. about his NEJM

Posted in - NEJM, Cardiac surgery, Emory, Oncology | Leave a comment

Hormone replacement therapy is safe and effective after all

November 14, 2017- Interviewed by Steven E. Greer, MD We interviewed JoAnn Manson, MD, DrPH about her JAMA paper that followed the cohorts in

Posted in - JAMA, Cardiology, Diabetes and endocrinology, FDA, Geriatrics, Harvard, Obstetrics and Gynecology, Oncology, Orthopedic surgery, Primary care medicine | Leave a comment

The new CDC guidelines for prescribing opioid pain pills

June 1, 2016- Interviewed by Steven E. Greer, MD Pain pill prescriptions have quadrupled since the 1990’s as drug companies stepped up marketing and funded

Posted in - JAMA, - NEJM, - Pharma, CDC, Emergency medicine, General surgery, Oncology, Psychology Psychiatry, Rehab, Spine surgery, Sports medicine | Leave a comment

The Who’s Teen Cancer Lounge at Sloan Kettering opens

March 18, 2016- by Steven E. Greer MD The Memorial Sloan Kettering Cancer Center held a press day for its new teen lounge

Posted in Memorial Sloan-Kettering, Oncology | Leave a comment

The Daltrey Townshend teenage and young adult cancer center at UCLA

May 4, 2014- Interviewed by Steven E. Greer More than 20 years ago, Roger Daltrey began forming special cancer units in the UK to treat patients in their teenage

Posted in - Opinion, Oncology, Rehab, UCLA | Leave a comment

Interview with the CEO of Galena Biopharma about cancer vaccines

February 8, 2016- Interviewed by Steven E. Greer, MD

Posted in - Biotech, Oncology | Leave a comment

What 1982’s Blade Runner got right about 2019

September 3, 2017- by Steven E. Greer, MD I watched again the 1982 classic Blade Runner. Directed by Ridley Scott and starring Harrison Ford,

Posted in - Opinion, - Reviews, books, devices, Genetics, Geriatrics, Obstetrics and Gynecology, Oncology, Ophthalmology | Leave a comment

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

February 27, 2017- interviewed by Steven E. Greer, MD We interviewed Joaquim Bellmunt, MD, PhD, the Director of the Bladder Cancer Center at Dana-Farber,

Posted in - Biotech, - NEJM, - Pharma, Harvard, Oncology | Leave a comment

The 23andMe home genetics test kit controversy

December 19, 2013- Interviewed by Steven E. Greer,  MD

Posted in Columbia, FDA, Genetics, NIH, Oncology, Psychology Psychiatry | Leave a comment

CheckMate 026: Why did Opdivo (nivolumab) fail in NSCLC?

September 1, 2016- Interviewed by Steven E. Greer, MD In the wake of the news-making failure of CheckMate 026 of Bristol-Myers Squibb’s Opdivo (nivolumab) fail in

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

January 12, 2017- Interviewed by Steven E. Greer, MD Jonathan Strosberg, MD of

Posted in - NEJM, Oncology | Leave a comment

Antoni Ribas, MD discusses cancer drugs targeting the PD1 signaling pathways

March 19, 2013- Interviewed by Steven E. Greer, MD The upcoming ASCO meeting will be dominated by numerous presentations relating to new

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

Review of combination immunotherapies seen at ASCO 2016

June 22, 2016- interviewed by Steven E. Greer, MD We interviewed Siwen Hu-Lieskovan MD, PhD of UCLA, an expert with immunotherapies for melanoma,

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

Ibrance (palbociclib) to treat advanced breast cancer

November 28, 2016- Interviewed by Steven E. Greer, MD We interviewed Richard Finn,

Posted in - Biotech, - NEJM, - Pharma, Oncology, UCLA | Leave a comment

Review of immunotherapy and targeted therapy

June 17, 2016- interviewed by Steven E. Greer, MD We interviewed Siwen Hu-Lieskovan MD, PhD of UCLA, an expert with immunotherapies for melanoma, to go over the

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

The telomerase inhibitor Imetelstat developed by Geron

September 9, 2015-

Posted in - Biotech, - NEJM, Oncology | Leave a comment

BRAF and MEK combos for melanoma

Update October 1, 2015- The FDA approved the use of two drugs, Opdivo and Yervoy, to treat metastatic melanoma, as we first discussed with Dr.  Ribas last year.

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

Brigham and Women’s Hospital engages in bizarre PR campaign for daily aspirin

 April 21, 2015- By Steven E. Greer, MD Brigham and Women’s Hospital in Boston, part of the Harvard University network of hospitals,

Posted in - Policy, Cardiology, Harvard, Neurology, Oncology | Leave a comment

Daily aspirin once again proves to be of no use and also deadly

Update January 13, 2015- Yet another study was published highlighting the risks of daily aspirin. 

Posted in - JAMA, - Pharma, - Policy, Cardiac surgery, Cardiology, Gastroenterology and liver, General surgery, Neurology, Neurosurgery, Oncology, Primary care medicine | Leave a comment

Interview with Simon Townshend about the Daltrey/Townshend Teen Cancer Program

The Daltrey Townshend teenage and young adult cancer center at UCLA

Posted in Oncology, UCLA | Leave a comment